

WORLDWIDE HEALTHCARE TRUST PLC

Interim Management Statement – 3 months to 31 December 2013 (unaudited)

Worldwide Healthcare Trust PLC invests in the global healthcare sector with the objective of achieving a high level of capital growth. In order to achieve its investment objective, the Company invests worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector.

The Company uses gearing and derivative transactions to mitigate risk and also enhance returns.

During the 3 month period ended 31 December 2013 the Company's fully diluted net asset value per share total return was 8.8%, in line with the Company's share price total return; both outperformed the Company's benchmark, the MSCI World Health Care Index measured in sterling terms on a total return basis, which rose by 6.4% during the period. Overall, exposure to North America and also to large capitalisation stocks was increased while holdings in Europe and small capitalisation stocks were reduced. At the stock level, the percentage holding in Gilead Sciences rose and a position in Regeneron Pharmaceuticals was established while those in Roche and Merck fell.

During the three-month period 211,349 new shares were issued, as a result of holders of subscription shares exercising their subscription rights, raising £1.5m of additional funds for the Company.

Since the period end, to the date of this report, 192,377 new shares were allotted, as a result of holders of subscription shares exercising their subscription rights, raising £1.3m of additional funds for the Company. As at 14 February 2014 there are 46,292,111 shares in issue. There are also 1,860,969 subscription shares in issue.

In the period from 31 December 2013 to 12 February 2014, the Company's fully diluted net asset value per share total return was 7.5%, compared to a return of 3.4% from the Company's benchmark. The share price total return was 4.6%.

A first interim dividend of 7.0p per share, for the year to 31 March 2014, was paid on 10 January 2014 to shareholders on the register of members on 6 December 2013. The associated ex-dividend date was 4 December 2013.

Trust Characteristics

	31 December 2013	30 September 2013
Number of holdings	62	57
Net assets (£m)	593.6	548.4
Indicative yield	1.3%	1.4%
Gearing (AIC basis)	11%	12%
Share price (p)	1239.00	1145.00
NAV (p) –undiluted (ex income)	1284 .59	1187.54
NAV (p) diluted: sub shares (ex income)	1259.62	1164.56
(Discount)/premium (undiluted)	(3.5%)	(3.6%)
(Discount)/premium(diluted – sub shares)	(1.6%)	(1.7%)
Subscription share price (p)	521.00	444.00

Source: Frostrow Capital LLP

10 Largest Investments

Name	% of portfolio at 31 December 2013	% of portfolio at 30 September 2013
Roche	7.2	7.6
Gilead Sciences	5.3	4.9
Regeneron Pharmaceuticals	3.8	-
HCA	3.6	2.7
Incyte	3.4	3.1
Merck & Co	3.4	4.5
Bristol-Myers Squibb	3.4	3.2
Mylan	3.4	3.3
Amgen	3.2	3.5
Biogen Idec	2.8	3.9
Total	39.5	36.7

Source: Frostrow Capital LLP

Sector Analysis

	% of portfolio at 31 December 2013	% of portfolio at 30 September 2013
Large capitalisation	74.5	68.7
Small capitalisation	25.5	31.3
Total	100.0	100.0

Source: Frostrow Capital LLP

Geographical Analysis

	% of portfolio at 31 December 2013	% of portfolio at 30 September 2013
North America	69.3	67.2
Europe	11.5	13.7
Asia	8.7	8.0
Emerging Markets	10.5	11.1
Total	100.0	100.0

Source: Frostrow Capital LLP

Total Return Performance to 31 December 2013

	3 Months	1 Year	3 Years	5 Years
Share price	+8.8%	+47.1%	+88.4%	+141.6%
NAV Fully diluted	+8.8%	+44.6%	+77.4%	+123.1%
Benchmark*	+6.4%	+33.6%	+66.1%	+88.3%

Source: NAV (total return; fully diluted) and Share Price (total return) Morningstar. Benchmark – Thomson Reuters and Bloomberg

*Benchmark – With effect from 1 October 2010, the performance of the Company is measured against the MSCI World Health Care Index on a total return, sterling adjusted basis. Prior to this date, performance was measured against the Datastream World Pharmaceutical and Biotechnology Index measured in sterling terms on a total return basis. Historic data, therefore, consists of a blended figure containing both indices.

Past performance is not a guide to future performance.

This Interim Management Statement has been prepared solely to provide information to meet the requirements of the UK Listing Authority's Disclosure and Transparency Rules.

This Interim Management Statement is available on the Company's website www.worldwidewh.com.

The Company's net asset value per share is announced daily and is available, together with the share price, on the Company's website www.worldwidewh.com and on the TrustNet website at www.trustnet.com

Identification Codes:

Ordinary Shares

SEDOL– 0338530

ISIN - GB0003385308

Bloomberg – WWH LN

EPIC - WWH

Subscription Shares

SEDOL – B3VMCB0

ISIN – GB00B3VMCB07

Bloomberg – WWHS LN

For further information contact: Mark Pope on 0203 008 4913

Frostrow Capital LLP

Company Secretary

14 February 2014